Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT01688960
Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT01639040
Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2013-10-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT01605708
A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT01604824
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT01576484
Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 109
- Registration Number
- NCT01548404
Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers
- First Posted Date
- 2012-02-28
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT01540539
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 183
- Registration Number
- NCT01521559
A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT01507402
Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers
Phase 1
Completed
- Conditions
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2012-03-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT01484600
© Copyright 2024. All Rights Reserved by MedPath